High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
0.00
-100%
-0.245
-43.02%
-83.33K
-102%
-0.267
-129.96%
--
--
-0.277
-27.19%
Estimates Revision
The market is revising Downward the revenue expectations for Century Therapeutics, Inc. (IPSC) for FY2025, with the revenue forecasts being adjusted by -0.01% over the past three months. During the same period, the stock price has changed by 4.18%.
Revenue Estimates for FY2025
Revise Downward
-0.01%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
-3.57%
In Past 3 Month
Stock Price
Go Up
+4.18%
In Past 3 Month
2 Analyst Rating
Wall Street analysts forecast IPSC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IPSC is 4.50 USD with a low forecast of 2.00 USD and a high forecast of 7.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.526
Low
2.00
Averages
4.50
High
7.00
Current: 0.526
Low
2.00
Averages
4.50
High
7.00
Leerink
Outperform -> Market Perform
downgrade
$7 -> $2
2025-11-17
Reason
Leerink
Price Target
$7 -> $2
2025-11-17
downgrade
Outperform -> Market Perform
Reason
Leerink downgraded Century Therapeutics to Market Perform from Outperform with a price target of $2, down from $7. The firm appreciates the strategic merits behind Century's de-prioritization of its sole clinical asset, CNTY-101, in favor of more innovative preclinical programs. However, the decision leaves the company without "value-inflecting clinical catalysts" over the next 12-15 months, the analyst tells investors in a research note. Leerink believes development progress for Century's preclinical programs will receive little credit from the market without clinical data.
HC Wainwright & Co.
Mitchell Kapoor
Strong Buy
Maintains
$5 → $2
2025-04-03
Reason
HC Wainwright & Co.
Mitchell Kapoor
Price Target
$5 → $2
2025-04-03
Maintains
Strong Buy
Reason
Guggenheim
Kelsey Goodwin
Strong Buy
Reiterates
n/a
2025-03-28
Reason
Guggenheim
Kelsey Goodwin
Price Target
n/a
2025-03-28
Reiterates
Strong Buy
Reason
Guggenheim analyst Kelsey Goodwin lowered the firm's price target on Century Therapeutics to $5 from $12 and keeps a Buy rating on the shares. Century Therapeutics reported FY24 results and a business update that included a pre-planned pipeline re-prioritization, and announced the discontinuation of CNTY-101 in relapsed and refractory non-Hodgkin lymphoma in the ELiPSE-1 trial, which was largely expected by the Street, the analyst tells investors in a research note. The firm views Century as a differentiated player in the large autoimmune space in the near-term, and a leader in the field of induced pluripotent stem cell-derived cell therapies longer term.
Chardan Capital
Geulah Livshits
Strong Buy
Maintains
$11 → $7
2025-03-24
Reason
Chardan Capital
Geulah Livshits
Price Target
$11 → $7
2025-03-24
Maintains
Strong Buy
Reason
Chardan lowered the firm's price target on Century Therapeutics to $7 from $11 and keeps a Buy rating on the shares. The company reported Q4 results and announced a pipeline re-prioritization, including discontinuation of the Phase I ELiPSE-1 trial evaluating the company's lead CD19 CAR-iNK candidate CNTY-01 in late-stage non-Hodgkin's lymphoma, the analyst tells investors in a research note. The firm cut the price target to reflect the pipeline prioritization.
Guggenheim
Kelsey Goodwin
Strong Buy
Maintains
$12 → $5
2025-03-21
Reason
Guggenheim
Kelsey Goodwin
Price Target
$12 → $5
2025-03-21
Maintains
Strong Buy
Reason
Guggenheim analyst Kelsey Goodwin lowered the firm's price target on Century Therapeutics to $5 from $12 and keeps a Buy rating on the shares. Century Therapeutics reported FY24 results and a business update that included a pre-planned pipeline re-prioritization, and announced the discontinuation of CNTY-101 in relapsed and refractory non-Hodgkin lymphoma in the ELiPSE-1 trial, which was largely expected by the Street, the analyst tells investors in a research note. The firm views Century as a differentiated player in the large autoimmune space in the near-term, and a leader in the field of induced pluripotent stem cell-derived cell therapies longer term.
Piper Sandler
Edward Tenthoff
Buy
Maintains
$4 → $2
2025-03-20
Reason
Piper Sandler
Edward Tenthoff
Price Target
$4 → $2
2025-03-20
Maintains
Buy
Reason
Piper Sandler analyst Edward Tenthoff lowered the firm's price target on Century Therapeutics to $2 from $4 and keeps an Overweight rating on the shares. Century will dose the first autoimmune disease patient in the Phase I CALiPSO-1 study of CD19 CAR-iNK CNTY-101 this month with initial data in 2025, the firm notes. Piper also highlights that Century discontinued the Phase I ELiPSE-1 study in r/rNHL to focus resources on autoimmune disease.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Century Therapeutics Inc (IPSC.O) is -0.49, compared to its 5-year average forward P/E of -3.41. For a more detailed relative valuation and DCF analysis to assess Century Therapeutics Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-3.41
Current PE
-0.49
Overvalued PE
0.78
Undervalued PE
-7.60
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-1.92
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
2.17
Undervalued EV/EBITDA
-6.01
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
34.56
Current PS
0.00
Overvalued PS
151.50
Undervalued PS
-82.39
Financials
Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
Trading Trends
Insider
Insiders areSelling! The selling amount has increased 2207.43% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areSelling! The selling amount has increased 179.43% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areSelling! The selling amount has increased 2207.43% over the last month.
Sold
Bought
IPSC News & Events
Events Timeline
(ET)
2025-11-13
07:33:12
Century Therapeutics announces Q3 earnings per share of 40 cents, compared to a loss of 37 cents in the same period last year.
2025-11-13
07:15:35
Century Therapeutics Launches New Beta Islet Initiative for Type 1 Diabetes
2025-01-21 (ET)
2025-01-21
06:18:16
Century announces investigator-initiated Phase 1/2 trial of CNTY-101
Sign Up For More Events
Sign Up For More Events
News
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/default_image/newsfilter.png)
Preview
9.0
11-13NewsfilterCentury Therapeutics Unveils New Beta Islet Initiative for Type 1 Diabetes
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/default_image/nasdaq.png)
Preview
4.0
07-22NASDAQ.COMAll You Need to Know About Century Therapeutics (IPSC) Rating Upgrade to Strong Buy
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/4074ee605596bdee0828f26b8f00790104d8a368eff82be96c06753fff89deca.png)
Preview
9.0
05-19WSJThe Top Corporate Board Directors
Sign Up For More News
People Also Watch
FAQ
What is Century Therapeutics Inc (IPSC) stock price today?
What is Century Therapeutics Inc (IPSC)'s business?
What is the price predicton of IPSC Stock?
What is Century Therapeutics Inc (IPSC)'s revenue for the last quarter?
What is Century Therapeutics Inc (IPSC)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Century Therapeutics Inc (IPSC)'s fundamentals?
How many employees does Century Therapeutics Inc (IPSC). have?